217 related articles for article (PubMed ID: 30458059)
1. A pilot trial of RNS60 in amyotrophic lateral sclerosis.
Paganoni S; Alshikho MJ; Luppino S; Chan J; Pothier L; Schoenfeld D; Andres PL; Babu S; Zürcher NR; Loggia ML; Barry RL; Luotti S; Nardo G; Trolese MC; Pantalone S; Bendotti C; Bonetto V; De Marchi F; Rosen B; Hooker J; Cudkowicz M; Atassi N
Muscle Nerve; 2019 Mar; 59(3):303-308. PubMed ID: 30458059
[TBL] [Abstract][Full Text] [Related]
2. Effect of RNS60 in amyotrophic lateral sclerosis: a phase II multicentre, randomized, double-blind, placebo-controlled trial.
Beghi E; Pupillo E; Bianchi E; Bonetto V; Luotti S; Pasetto L; Bendotti C; Tortarolo M; Sironi F; Camporeale L; Sherman AV; Paganoni S; Scognamiglio A; De Marchi F; Bongioanni P; Del Carratore R; Caponnetto C; Diamanti L; Martinelli D; Calvo A; Filosto M; Padovani A; Piccinelli SC; Ricci C; Dalla Giacoma S; De Angelis N; Inghilleri M; Spataro R; La Bella V; Logroscino G; Lunetta C; Tarlarini C; Mandrioli J; Martinelli I; Simonini C; Zucchi E; Monsurrò MR; Ricciardi D; Trojsi F; Riva N; Filippi M; Simone IL; Sorarù G; Spera C; Florio L; Messina S; Russo M; Siciliano G; Conte A; Saddi MV; Carboni N; Mazzini L;
Eur J Neurol; 2023 Jan; 30(1):69-86. PubMed ID: 36148821
[TBL] [Abstract][Full Text] [Related]
3. RNS60 exerts therapeutic effects in the SOD1 ALS mouse model through protective glia and peripheral nerve rescue.
Vallarola A; Sironi F; Tortarolo M; Gatto N; De Gioia R; Pasetto L; De Paola M; Mariani A; Ghosh S; Watson R; Kalmes A; Bonetto V; Bendotti C
J Neuroinflammation; 2018 Mar; 15(1):65. PubMed ID: 29495962
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial.
Gold J; Rowe DB; Kiernan MC; Vucic S; Mathers S; van Eijk RPA; Nath A; Garcia Montojo M; Norato G; Santamaria UA; Rogers ML; Malaspina A; Lombardi V; Mehta PR; Westeneng HJ; van den Berg LH; Al-Chalabi A
Amyotroph Lateral Scler Frontotemporal Degener; 2019 Nov; 20(7-8):595-604. PubMed ID: 31284774
[No Abstract] [Full Text] [Related]
5. Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial.
Babu S; Hightower BG; Chan J; Zürcher NR; Kivisäkk P; Tseng CJ; Sanders DL; Robichaud A; Banno H; Evora A; Ashokkumar A; Pothier L; Paganoni S; Chew S; Dojillo J; Matsuda K; Gudesblatt M; Berry JD; Cudkowicz ME; Hooker JM; Atassi N
Neuroimage Clin; 2021; 30():102672. PubMed ID: 34016561
[TBL] [Abstract][Full Text] [Related]
6. Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [(11)C]-PBR28.
Zürcher NR; Loggia ML; Lawson R; Chonde DB; Izquierdo-Garcia D; Yasek JE; Akeju O; Catana C; Rosen BR; Cudkowicz ME; Hooker JM; Atassi N
Neuroimage Clin; 2015; 7():409-14. PubMed ID: 25685708
[TBL] [Abstract][Full Text] [Related]
7. Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS).
Mandrioli J; Crippa V; Cereda C; Bonetto V; Zucchi E; Gessani A; Ceroni M; Chio A; D'Amico R; Monsurrò MR; Riva N; Sabatelli M; Silani V; Simone IL; Sorarù G; Provenzani A; D'Agostino VG; Carra S; Poletti A
BMJ Open; 2019 May; 9(5):e028486. PubMed ID: 31152038
[TBL] [Abstract][Full Text] [Related]
8. Integrated imaging of [
Ratai EM; Alshikho MJ; Zürcher NR; Loggia ML; Cebulla CL; Cernasov P; Reynolds B; Fish J; Seth R; Babu S; Paganoni S; Hooker JM; Atassi N
Neuroimage Clin; 2018; 20():357-364. PubMed ID: 30112276
[TBL] [Abstract][Full Text] [Related]
9. Mecasin treatment in patients with amyotrophic lateral sclerosis: study protocol for a randomized controlled trial.
Kim S; Kim JK; Son MJ; Kim D; Song B; Son I; Kang HW; Lee J; Kim S
Trials; 2018 Apr; 19(1):225. PubMed ID: 29653550
[TBL] [Abstract][Full Text] [Related]
10. Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial.
Park SB; Vucic S; Cheah BC; Lin CS; Kirby A; Mann KP; Zoing MC; Winhammar J; Kiernan MC
EBioMedicine; 2015 Dec; 2(12):1916-22. PubMed ID: 26844270
[TBL] [Abstract][Full Text] [Related]
11. An open label pilot study of the safety and tolerability of perampanel in amyotrophic lateral sclerosis.
Hotait M; Ismail HH; Saab GE; Salameh JS
Muscle Nerve; 2021 Oct; 64(4):504-508. PubMed ID: 34322897
[TBL] [Abstract][Full Text] [Related]
12. Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability.
Berry JD; Paganoni S; Atassi N; Macklin EA; Goyal N; Rivner M; Simpson E; Appel S; Grasso DL; Mejia NI; Mateen F; Gill A; Vieira F; Tassinari V; Perrin S
Muscle Nerve; 2017 Dec; 56(6):1077-1084. PubMed ID: 28662296
[TBL] [Abstract][Full Text] [Related]
13. Open label study to assess the safety of VM202 in subjects with amyotrophic lateral sclerosis.
Sufit RL; Ajroud-Driss S; Casey P; Kessler JA
Amyotroph Lateral Scler Frontotemporal Degener; 2017 May; 18(3-4):269-278. PubMed ID: 28166654
[TBL] [Abstract][Full Text] [Related]
14. A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis: Efficacy and safety of sodium channel blocker phase II trial.
Shibuya K; Misawa S; Kimura H; Noto Y; Sato Y; Sekiguchi Y; Iwai Y; Mitsuma S; Beppu M; Watanabe K; Fujimaki Y; Tsuji Y; Shimizu T; Mizuno T; Nakagawa M; Sawaguchi K; Hanaoka H; Kuwabara S
Amyotroph Lateral Scler Frontotemporal Degener; 2015; 16(5-6):353-8. PubMed ID: 25960085
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study.
de la Rubia JE; Drehmer E; Platero JL; Benlloch M; Caplliure-Llopis J; Villaron-Casales C; de Bernardo N; AlarcÓn J; Fuente C; Carrera S; Sancho D; GarcÍa-Pardo P; Pascual R; JuÁrez M; Cuerda-Ballester M; Forner A; Sancho-Castillo S; Barrios C; Obrador E; Marchio P; Salvador R; Holmes HE; Dellinger RW; Guarente L; Estrela JM
Amyotroph Lateral Scler Frontotemporal Degener; 2019 Feb; 20(1-2):115-122. PubMed ID: 30668199
[TBL] [Abstract][Full Text] [Related]
16. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
[TBL] [Abstract][Full Text] [Related]
17. Nebulization of RNS60, a Physically-Modified Saline, Attenuates the Adoptive Transfer of Experimental Allergic Encephalomyelitis in Mice: Implications for Multiple Sclerosis Therapy.
Mondal S; Rangasamy SB; Ghosh S; Watson RL; Pahan K
Neurochem Res; 2017 May; 42(5):1555-1570. PubMed ID: 28271325
[TBL] [Abstract][Full Text] [Related]
18. Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients.
Imamura K; Izumi Y; Banno H; Uozumi R; Morita S; Egawa N; Ayaki T; Nagai M; Nishiyama K; Watanabe Y; Hanajima R; Oki R; Fujita K; Takahashi N; Ikeda T; Shimizu A; Morinaga A; Hirohashi T; Fujii Y; Takahashi R; Inoue H
BMJ Open; 2019 Dec; 9(12):e033131. PubMed ID: 31796494
[TBL] [Abstract][Full Text] [Related]
19. A phase II open label clinical study of the safety, tolerability and efficacy of ILB® for Amyotrophic Lateral Sclerosis.
Logan A; Nagy Z; Barnes NM; Belli A; Di Pietro V; Tavazzi B; Lazzarino G; Lazzarino G; Bruce L; Persson LI
PLoS One; 2022; 17(5):e0267183. PubMed ID: 35613082
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-1 Antagonist Anakinra in Amyotrophic Lateral Sclerosis--A Pilot Study.
Maier A; Deigendesch N; Müller K; Weishaupt JH; Krannich A; Röhle R; Meissner F; Molawi K; Münch C; Holm T; Meyer R; Meyer T; Zychlinsky A
PLoS One; 2015; 10(10):e0139684. PubMed ID: 26444282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
